Moreover, overall survival rates of patients with ccRCC, who were treated with everolimus (mTOR inhibitor), showed no significant difference based on RBFOX2 mRNA levels in the PBRM1 WT group (Fig. 6I). This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.